Viridian Therapeutics, Inc.\DE (VRDN) EBT Margin (2013 - 2026)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly EBT Margin came in at 79261.7% in Q1 2026, up 5151746.0% year-on-year from N/an in Q1 2025, and down 5.68% quarter-over-quarter from 75003.79% in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) EBT Margin (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's EBT Margin history runs 14 years deep, the most recent figure standing at 79261.7% for Q1 2026.
- On a quarterly basis, EBT Margin rose 5151746.0% year-over-year to 79261.7% in Q1 2026; TTM through Mar 2026 was 504.08%, a 11131778.0% increase from a year earlier, with the FY2025 full-year figure at 921.42%, up 15667758.0% from the prior year.
- EBT Margin declined to 79261.7% in Q1 2026 per VRDN's latest filing, from 75003.79% in the prior quarter.
- Across five years, EBT Margin topped out at 49.67% in Q3 2025 and bottomed at 148888.0% in Q2 2025.
- The 5-year median for EBT Margin is 76476.39% (2023), against an average of 72359.56%.
- Across the five-year window, EBT Margin tumbled 7349433 bps in 2023 and surged 10633289 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 43420.95% in 2022, then sank by 169 bps to 116915.28% in 2023, then grew by 6 bps to 109850.0% in 2024, then jumped by 32 bps to 75003.79% in 2025, then dropped by 6 bps to 79261.7% in 2026.
- Per Business Quant, the three latest VRDN EBT Margin figures stand at 79261.7% (Q1 2026), 75003.79% (Q4 2025), and 49.67% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 33.74% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Viridian Therapeutics, Inc.\DE | 631.55 Mn | 631.55 Mn | - | -79,261.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79,261.70% |
| Dec 31, 2025 | -75,003.79% |
| Sep 30, 2025 | -49.67% |
| Jun 30, 2025 | -148,888.00% |
| Mar 31, 2025 | -130,779.17% |
| Dec 31, 2024 | -109,850.00% |
| Sep 30, 2024 | -106,382.56% |
| Jun 30, 2024 | -101,333.33% |
| Mar 31, 2024 | -80,125.00% |
| Dec 31, 2023 | -116,915.28% |
| Sep 30, 2023 | -66,194.44% |
| Jun 30, 2023 | -76,476.39% |
| Mar 31, 2023 | -69,577.55% |
| Dec 31, 2022 | -43,420.95% |
| Sep 30, 2022 | -2,421.84% |
| Jun 30, 2022 | -11,537.89% |
| Mar 31, 2022 | -11,894.91% |
| Dec 31, 2021 | -13,618.22% |
| Sep 30, 2021 | -6,751.44% |
| Jun 30, 2021 | -1,648.07% |